Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H24ClNO |
Molecular Weight | 329.864 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(C=C1)C(OCCN2CCCCC2)C3=CC=CC=C3
InChI
InChIKey=FLNXBVJLPJNOSI-UHFFFAOYSA-N
InChI=1S/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21445282
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21445282
Cloperastine (INN) or cloperastin is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.
CNS Activity
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20460867 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Ameliorating effects of cloperastine on dysfunction of the urinary bladder caused by cerebral infarction in conscious rats. | 2009 Nov |
|
Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. | 2010 Feb 5 |
|
[Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats]. | 2010 May |
|
Cloperastine-based cough syrup and acute dystonic reactions. | 2012 Mar |
|
Cloperastine rescues impairment of passive avoidance response in mice prenatally exposed to diethylstilbestrol. | 2014 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21445282
10–20 mg three times daily for adults
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23047467
Cloperastine inhibited the hERG K⁺ channels, expressed in HEK293 cells, in a concentration-dependent manner with an IC₅₀ value of 0.027 μM
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R05DB21
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
||
|
WHO-VATC |
QR05DB21
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CLOPERASTINE
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
2423
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
758635
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
2805
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
DB09002
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL415087
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
100000084016
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
C040282
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
DTXSID7048532
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
C78106
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
2104180
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
m3654
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
223-042-3
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
69M5L7BXEK
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
SUB06737MIG
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
3703-76-2
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
69M5L7BXEK
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY | |||
|
707
Created by
admin on Sat Dec 16 16:45:05 GMT 2023 , Edited by admin on Sat Dec 16 16:45:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)